抑制雄激素受体暴露在前列腺癌中的复制应激脆弱性
bioRxiv : the preprint server for biology
|October 17, 2024
概括
转移性前列腺癌的雄激素受体通路抑制剂 (ARPI) 导致DNA复制压力. 将恩扎胺与转化DNA合成抑制剂JH-RE-06结合起来,通过利用这种脆弱性,有效抑制瘤生长.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 癌症治疗方法 癌症治疗方法
背景情况:
- 转移性前列腺癌的治疗通常涉及雄激素受体 (AR) 信号抑制剂.
- 对AR途径抑制剂 (ARPIs) 的获得性耐药性是一个主要的临床挑战.
- 标准的ARPI如恩扎胺最初是有效的,但抗药性发展.
研究的目的:
- 研究前列腺癌中ARPI耐药性背后的分子机制.
- 探索在组合疗法中准DNA复制应激和转化DNA合成 (TLS) 的潜力.
- 为了评估结合恩扎胺与TLS抑制剂的疗效.
主要方法:
- 治疗AR阳性前列腺癌细胞使用恩扎胺来诱导DNA复制压力.
- 评估单链DNA (ssDNA) 缺口和DNA损伤生物标志物.
- 在体外测试TLS抑制剂JH-RE-06与恩扎胺结合使用.
- 综合疗法的疗效评估在一个突发性小鼠瘤模型中.
主要成果:
- 恩扎胺治疗会在AR阳性前列腺癌细胞中诱导DNA复制应激.
- 抑制转化DNA合成 (TLS) 会加剧这种压力,导致DNA受损.
- 在体外,TLS抑制剂JH-RE-06使AR阳性前列腺癌细胞对恩扎胺敏感.
- 组合疗法在临床前小鼠模型中显著抑制了瘤生长.
结论:
- 抗雄激素受体抑制引发激素敏感前列腺癌中的DNA复制应激.
- 向转化DNA合成 (TLS) 是ARPI治疗的一个可行的辅助策略.
- 恩扎胺与TLS抑制剂的结合为转移性前列腺癌提供了一个有前途的治疗方法.
相关概念视频
Negative Regulator Molecules
35.2K
Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
35.2K
The DNA Replication Fork
35.6K
An organism’s genome needs to be duplicated in an efficient and error-free manner for its growth and survival. The replication fork is a Y-shaped active region where two strands of DNA are separated and replicated continuously. The coupling of DNA unzipping and complementary strand synthesis is a characteristic feature of a replication fork. Organisms with small circular DNA, such as E. coli, often have a single origin of replication; therefore, they have only two replication...
35.6K
DNA Damage can Stall the Cell Cycle
9.1K
In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
9.1K
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
Abnormal Proliferation
4.5K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
Inhibition of Cdk Activity
4.7K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K


